MDLinxManaging Extreme LDL-C: Targeted Therapies for Genetic Dyslipidemias

Familial hypercholesterolemia (FH) is among the most common genetic disorders, yet 70% of patients remain undiagnosed and the average patient experiences a cardiac event around age 47. Extreme LDL-C above 190 mg/dL in a young patient with family history warrants genetic workup, not lifestyle counseling alone.

Clinical Considerations

• Healthy LDL-C sits below 100 mg/dL; with family history of atherosclerosis, the target drops to 70 mg/dL or lower.
• The Family Heart Foundation’s FIND FH program integrated machine learning with lipid levels, family history, and clinician notes to surface undiagnosed patients across five sites.
• Homozygous FH is inherited from both parents and often requires lipoprotein apheresis, a dialysis-like procedure; heterozygous FH responds to layered pharmacotherapy.
• A 2025 Current Atherosclerosis Reports review notes survival has extended by years with PCSK9 inhibitors, ezetimibe, evinacumab (ANGPTL3 inhibitor), and lomitapide.

Practice Applications

• Recognize extreme LDL-C plus early family cardiac history as a genetic signal.
• Consider cascade screening of first-degree relatives when FH is suspected.
• Integrate PCSK9 inhibitors with statins and ezetimibe when LDL-C goals are unmet.
• Refer homozygous FH patients to lipid specialists for apheresis evaluation.

Related Reading